Product Description
Merck was developing mk-8723, an intravenous agent for Immune Thrombocytopenia Purpura
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01963260 |
MK-8723-001 | P1 |
Completed |
Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia |
2015-04-26 |
2022-05-04 |
Recent News Events
Date |
Type |
Title |
|---|